Search

Your search keyword '"Novartis Pharma AG -- Reports"' showing total 11 results
Start Over Descriptor "Novartis Pharma AG -- Reports" Journal financial law reporter
11 results on '"Novartis Pharma AG -- Reports"'

1. FORM 8-K: Olema Pharmaceuticals, Inc. Files Current Report (Dec 02, 2024)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Employers -- Reports, Securities law -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, News, opinion and commentary
Abstract

Washington: Olema Pharmaceuticals, Inc., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Dec 02, 2024: UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 [...]

Published
2024

2. FORM 8-K: Voyager Therapeutics, Inc. Files Current Report (Sep 05, 2024)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Securities law -- Reports, Stock-exchange -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: Voyager Therapeutics, Inc., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Sep 05, 2024: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 [...]

Published
2024

3. FORM 8-K: ARVINAS, INC. Files Current Report (May 30, 2024)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Securities law -- Reports, Stock-exchange -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: ARVINAS, INC., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on May 30, 2024: UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________ [...]

Published
2024

4. FORM 8-K: BeiGene, Ltd. Files Current Report (Sep 19, 2023)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Securities law -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, Securities industry -- Reports, Pharmaceutical industry -- Reports, Securities industry, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: BeiGene, Ltd., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Sep 19, 2023: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ [...]

Published
2023

5. FORM 8-K: BeiGene, Ltd. Files Current Report (Jul 11, 2023)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Securities law -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, Securities industry -- Reports, Securities industry, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: BeiGene, Ltd., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Jul 11, 2023: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ [...]

Published
2023

6. FORM 8-K: SomaLogic, Inc. Files Current Report (Jan 10, 2023)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, SomaLogic Inc. -- Reports, Securities law -- Reports, Biotechnology industry -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: SomaLogic, Inc., has filed FORM 8-K (Current Report) with Securities and Exchange Commission on Jan 10, 2023: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT [...]

Published
2023

7. FORM 8-K: IONIS PHARMACEUTICALS, INC. Files Current Report (Jan 09, 2023)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Ionis Pharmaceuticals, Inc. -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: IONIS PHARMACEUTICALS, INC., has filed FORM 8-K (Current Report) with Securities and Exchange Commission on Jan 09, 2023: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K [...]

Published
2023

8. FORM 8-K: ALLARITY THERAPEUTICS, INC. Files Current Report (Sep 30, 2022)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Securities law -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: ALLARITY THERAPEUTICS, INC., has filed FORM 8-K (Current Report) with Securities and Exchange Commission on Sep 30, 2022: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K [...]

Published
2022

9. FORM 8-K: Precision BioSciences, Inc. Files Current Report (Updated on JUL 18, 2022)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Securities law -- Reports, Biotechnology industry -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: Precision BioSciences, Inc., has filed FORM 8-K (Current Report) with Securities and Exchange Commission on JUL 18, 2022: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K [...]

Published
2022

10. FORM 8-K: Mallinckrodt plc Files Current Report (Updated on JUN 30, 2022)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Stratatech Corp. -- Reports, Mallinckrodt PLC -- Reports, Biological products industry -- Reports, Securities law -- Reports, Financial statements -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: Mallinckrodt plc, has filed FORM 8-K (Current Report) with Securities and Exchange Commission on JUN 30, 2022: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT [...]

Published
2022

11. FORM 8-K: Precision BioSciences, Inc. Files Current Report (Updated on JUN 21, 2022)

Subjects
United States. Securities and Exchange Commission -- Reports, Novartis Pharma AG -- Reports, Employers -- Reports, Securities law -- Reports, Biotechnology industry -- Reports, Pharmaceutical industry -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: Precision BioSciences, Inc., has filed FORM 8-K (Current Report) with Securities and Exchange Commission on JUN 21, 2022: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results